Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LFCR 
Lifecore Biomedical Inc. (LFCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: LFCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.04% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 243.16M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 3 | Beta 0.62 | 52 Weeks Range 4.76 - 8.85 | Updated Date 10/19/2025 |
52 Weeks Range 4.76 - 8.85 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Earnings Date
Report Date 2025-10-02 | When Before Market | Estimate -0.305 | Actual - |
Profitability
Profit Margin -30.04% | Operating Margin (TTM) 7.96% |
Management Effectiveness
Return on Assets (TTM) -3.04% | Return on Equity (TTM) -76.41% |
Valuation
Trailing PE - | Forward PE 8.67 | Enterprise Value 387070445 | Price to Sales(TTM) 1.89 |
Enterprise Value 387070445 | Price to Sales(TTM) 1.89 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA 8.11 | Shares Outstanding 37466352 | Shares Floating 19838916 |
Shares Outstanding 37466352 | Shares Floating 19838916 | ||
Percent Insiders 1.91 | Percent Institutions 75.5 |
Upturn AI SWOT
Lifecore Biomedical Inc.
Company Overview
History and Background
Lifecore Biomedical Inc. was founded in 1965 as Land O'Lakes Creameries, and later evolved into a biomedical company. It has a history of developing and manufacturing pharmaceutical-grade hyaluronic acid (HA) and biopolymers. Over time, it has focused on becoming a leading contract development and manufacturing organization (CDMO).
Core Business Areas
- Hyaluronic Acid (HA): Lifecore develops and manufactures high-quality, pharmaceutical-grade HA for use in medical devices and injectable pharmaceuticals.
- Contract Development and Manufacturing Organization (CDMO): Lifecore provides CDMO services to pharmaceutical and medical device companies, including formulation development, sterile fill-finish, and final packaging.
Leadership and Structure
Lifecore's leadership team consists of experienced professionals in the pharmaceutical and medical device industries. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Hyaluronic Acid (HA): Lifecore's HA is used in various medical applications, including ophthalmology, orthopedics, and dermatology. Market share is difficult to determine precisely due to the fragmented nature of the HA market, but Lifecore is considered a key player. Competitors include Fidia Farmaceutici, Seikagaku Corporation, and Allergan Aesthetics. Revenue from this segment constitutes a significant portion of their business.
- CDMO Services: Lifecore provides sterile fill-finish and other CDMO services for injectable drugs and medical devices. Market share data for this specific segment within the broader CDMO market is not readily available, but Lifecore competes with companies like Catalent, Thermo Fisher Scientific, and Recipharm.
Market Dynamics
Industry Overview
The pharmaceutical and medical device industries are experiencing steady growth, driven by an aging population, increasing demand for advanced therapies, and technological advancements. The CDMO market is also expanding as pharmaceutical companies increasingly outsource manufacturing activities.
Positioning
Lifecore is positioned as a specialized CDMO with expertise in handling complex sterile injectables and HA-based products. Its competitive advantage lies in its high-quality HA manufacturing capabilities and its focus on niche market segments.
Total Addressable Market (TAM)
The overall pharmaceutical CDMO market is estimated to be worth hundreds of billions of USD. Lifecore is positioned to capitalize on its area of specialization.
Upturn SWOT Analysis
Strengths
- Specialized expertise in HA manufacturing
- Strong CDMO capabilities for sterile injectables
- Established relationships with pharmaceutical and medical device companies
- High-quality manufacturing standards
Weaknesses
- Relatively small size compared to larger CDMO competitors
- Dependence on a limited number of key customers
- Potential for fluctuations in demand for HA-based products
Opportunities
- Expanding CDMO services to new pharmaceutical and medical device companies
- Developing new HA-based products and applications
- Acquiring complementary businesses to expand capabilities and market reach
- Capitalizing on the growing demand for injectable drug delivery systems
Threats
- Increased competition from larger CDMOs
- Changes in regulatory requirements for pharmaceutical manufacturing
- Price pressure from generic drug manufacturers
- Economic downturn affecting demand for medical devices and pharmaceuticals
Competitors and Market Share
Key Competitors
- Catalent (CTLT)
- Thermo Fisher Scientific (TMO)
- Recipharm (RECI-B.ST)
- Fidia Farmaceutici
- Seikagaku Corporation
- Allergan Aesthetics (ABBV)
Competitive Landscape
Lifecore has a competitive advantage in HA manufacturing and specialized CDMO services. However, it faces challenges from larger, more diversified CDMOs with greater resources and broader service offerings. Its focus on niche market segments can provide a degree of insulation from direct competition with larger players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require access to Lifecore Biomedical Inc.'s past financial statements and market performance data.
Future Projections: Future growth projections require access to analyst estimates and company guidance.
Recent Initiatives: Recent initiatives would involve access to the latest news, press releases, and company announcements.
Summary
Lifecore Biomedical is a specialized CDMO known for its hyaluronic acid (HA) expertise, with a focus on sterile injectables. While it has strong technical capabilities and established relationships, it faces competition from larger CDMOs and potential market fluctuations. Lifecore can expand through strategic acquisitions, new HA applications, and expansion into CDMO services.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- SEC Filings
- Third-Party Market Research
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Market conditions and company performance can change rapidly. Market share estimates are approximate due to data limitations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lifecore Biomedical Inc.
Exchange NASDAQ | Headquaters Chaska, MN, United States | ||
IPO Launch date 1996-02-15 | President, CEO & Director Mr. Paul Josephs | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 406 | Website https://www.lifecore.com |
Full time employees 406 | Website https://www.lifecore.com | ||
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.